Histone deacetylase inhibitor SAHA-induced epithelial-mesenchymal transition by upregulating Slug in lung cancer cells

Anti-Cancer Drugs

Volumn 29, Issue 1, 2018, Pages 80-88

  Wang, Jun ^a,b   Xu, Mei Qing ^b   Jiang, Xian Liang ^b   Mei, Xin Yu ^b   Liu, Xue Gang ^c  

^a SHANDONG UNIVERSITY   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

^c BENGBU MEDICAL COLLEGE   (China)

Author keywords

Epithelial mesenchymal transitions; Metastasis; SAHA; Slug

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SLUG; UVOMORULIN; VIMENTIN; VORINOSTAT; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; SNAI1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SNAIL;

ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CARCINOMA; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; A-549 CELL LINE; CELL MOTION; DRUG EFFECT; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

A549 CELLS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; SNAIL FAMILY TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 85042698501     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000573     Document Type: Article

References (36)

1. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin 2016;66:271-289.
2. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-890.
3. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-1428.
4. Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 2009;1796:75-90.
5. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131-142.
6. Liang X. EMT: new signals from the invasive front. Oral Oncol 2011;47:686-687.
7. Christofori G. New signals from the invasive front. Nature 2006;441:444-450.
8. Gurzu S, Turdean S, Kovecsi A, Contac AO, Jung I. Epithelial-mesenchymal, mesenchymal-epithelial, and endothelial-mesenchymal transitions in malignant tumors: an update. World J Clin Cases 2015;3:393-404.
9. Lahat G, Lubezky N, Loewenstein S, Nizri E, Gan S, Pasmanik-Chor M, et al. Epithelial-to-mesenchymal transition (EMT) in intraductal papillary mucinous neoplasm (IPMN) is associated with high tumor grade and adverse outcomes. Ann Surg Oncol 2014;21(Suppl):S750-S757.
10. Bae YK, Kim A, Kim MK, Choi JE, Kang SH, Lee SJ. Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer. Hum Pathol 2013;44:2028-2037.
11. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007;7:415-428.
12. Shih JY, Yang PC. The EMT regulator slug and lung carcinogenesis. Carcinogenesis 2011;32:1299-1304.
13. Ye Y, Xiao Y, Wang W, Yearsley K, Gao JX, Shetuni B, Barsky SH. ERalpha signaling through slug regulates E-cadherin and EMT. Oncogene 2010;29:1451-1462.
14. Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 2002;62:1613-1618.
15. Emadi Baygi M, Soheili ZS, Essmann F, Deezagi A, Engers R, Goering W, Schulz WA. Slug/SNAI2 regulates cell proliferation and invasiveness of metastatic prostate cancer cell lines. Tumour Biol 2010;31:297-307.
16. Sun Y, Song GD, Sun N, Chen JQ, Yang SS. Slug overexpression induces stemness and promotes hepatocellular carcinoma cell invasion and metastasis. Oncol Lett 2014;7:1936-1940.
17. Grzegrzolka J, Biala M, Wojtyra P, Kobierzycki C, Olbromski M, Gomulkiewicz A, et al. Expression of EMT markers SLUG and TWIST in breast cancer. Anticancer Res 2015;35:3961-3968.
18. Gu A, Jie Y, Yao Q, Zhang Y, Mingyan E. Slug is associated with tumor metastasis and angiogenesis in ovarian cancer. Reprod Sci 2017;24:291-299.
19. Uygur B, Wu WS. SLUG promotes prostate cancer cell migration and invasion via CXCR4/CXCL12 axis. Mol Cancer 2011;10:139.
20. Chavan AV, Somani RR. HDAC inhibitors - new generation of target specific treatment. Mini Rev Med Chem 2010;10:1263-1276.
21. Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007;16:1111-1120.
22. Botrugno OA, Santoro F, Minucci S. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett 2009;280:134-144.
23. Stimson L, La Thangue NB. Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett 2009;280:177-183.
24. Kao SH, Wang WL, Chen CY, Chang YL, Wu YY, Wang YT, et al. GSK3beta controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug. Oncogene 2014;33:3172-3182.
25. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, Hung MC. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 2004;6:931-940.
26. Bachelder RE, Yoon SO, Franci C, de Herreros AG, Mercurio AM. Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J Cell Biol 2005;168:29-33.
27. Dominguez D, Montserrat-Sentis B, Virgos-Soler A, Guaita S, Grueso J, Porta M, et al. Phosphorylation regulates the subcellular location and activity of the snail transcriptional repressor. Mol Cell Biol 2003;23:5078-5089.
28. Ni X, Li L, Pan G. HDAC inhibitor-induced drug resistance involving ATP-binding cassette transporters (Review). Oncol Lett 2015;9:515-521.
29. Wang H, Huang C, Zhao L, Zhang H, Yang JM, Luo P, et al. Histone deacetylase inhibitors regulate P-gp expression in colorectal cancer via transcriptional activation and mRNA stabilization. Oncotarget 2016;7:49848-49858.
30. Jiang GM, Wang HS, Zhang F, Zhang KS, Liu ZC, Fang R, et al. Histone deacetylase inhibitor induction of epithelial-mesenchymal transitions via upregulation of Snail facilitates cancer progression. Biochim Biophys Acta 2013;1833:663-671.
31. Kong D, Ahmad A, Bao B, Li Y, Banerjee S, Sarkar FH. Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells. PLoS One 2012;7:e45045.
32. Catalano MG, Fortunati N, Pugliese M, Marano F, Ortoleva L, et al. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2012;97:E1150-E1159.
33. Yoshikawa M, Hishikawa K, Idei M, Fujita T. Trichostatin a prevents TGF-beta1-induced apoptosis by inhibiting ERK activation in human renal tubular epithelial cells. Eur J Pharmacol 2010;642:28-36.
34. Wu Y, Starzinski-Powitz A, Guo SW. Trichostatin A, a histone deacetylase inhibitor, attenuates invasiveness and reactivates E-cadherin expression in immortalized endometriotic cells. Reprod Sci 2007;14:374-382.
35. He XQ, Wang LY, Riedel HM, Wang K, Yang Y, Dinu CZ, Rojanasakul Y. Mesothelin promotes epithelial-to-mesenchymal transition and tomorigenicity of human lung cancer and mesothelioma cells. Mol Cancer 2017;16:63-76.
36. Xiao J, Mu JS, Liu TR, Xu HN. Dig the root of cancer: targeting cancer stem cells therapy. J Med Discov 2017;2:jmd17003.